Salwa Ahmed Elgebaly
Nour Heart Institute,USA
Biography
Salwa Elgebaly graduated from the University of Alexandria Faculty of Pharmacy and holds a Master’s Degree from the University of Wisconsin Faculty of Medicine in Madison, Wisconsin; and a PhD from the University of North Carolina, Faculty of Pharmacy at Chapel Hill, North Carolina. She is a former Associate Professor at the University of Connecticut School of Medicine and she is currently the Executive Director of Nour Heart Institute (subsidiary of Nour Heart, Inc.). Dr. Elgebaly is the Inventor of 9 Patents Issued by the U.S. Patent Office.
Dr. Elgebaly identified and patented the potent inflammatory mediator, Nourin as a key ‘initial signal’ in early reperfusion injury. Her research targets the development of new therapy for patients with Ischemic Heart Diseases (IHD). She is currently developing a new combined therapy of the anti-inflammatory Nourexin™ (Nourin specific competitive antagonist) and the anti-apoptotic Nourexal™ (ATP preservation during ischemia) to protect AMI patients from reperfusion injury.
Abstract
Abstract : Nourexalâ„¢: A novel anti-inflammatory / antiapoptotic therapy against reperfusion injury
